Radiation Dose to Patients from Radiopharmaceuticals

Ahlgren L. Ivarsson S. Johansson L. Mattsson S. Nosslin B. (1985). Excretion of radionuclides in human breast milk after the administration of radiopharmaceuticals. J. Nucl. Med. 26, 1085–1090.

ARSAC (1984). Administration of Radioactive Substances Advisory Committee. Notes for Guidance on the Administration of Radioactive Substances to Persons for Purposes of Diagnosis, Treatment or Research, EN(84)5. Published by Dept of Health and Social Security, London.

Berman M. (1977). Kinetic Models for Absorbed Dose Calculation, Medical Internal Radiation Committee (MIRD) Pamphlet No. 12. Available from Society of Nuclear Medicine, 475 Park Avenue South, New York, NY 10016, USA.

Cloutier R. J. Watson E. E. Rohrer R. H. Smith E. M. (1973). Calculating the radiation dose to an organ. J. Nucl. Med. 14, 53–55.

Coakley A. J. Mountford P. J. (1985). Nuclear medicine and the nursing mother. Br. Med. J. 291, 159–160.

Coffey J. L. Watson E. E. (1979). Calculating doses from remaining body activity. A comparison of two methods. Med. Phys. 6, 307–308.

Garby L. Löfveberg S. Nosslin B. (1969). Radiation Doses from Radioactive Substances in Medical Use. Swedish National Institute of Radiation Protection, Stockholm (in Swedish).

Gelfand M. J. Thomas S. R. Kereiakes J. G. (1983). Absorbed radiation dose from routine imaging of the skeleton in children. Ann. Radiol 26, 421–423.

IAEA (1984). The Quality Control of Nuclear Medicine Instruments, Technical Document No. 317. International Atomic Energy Agency, Vienna, Austria.

ICRP (1971). Protection of the Patient in Radionuclide Investigations, ICRP Publication 17. Pergamon, Oxford.

ICRP (1973). Alkaline Earth Metabolism in Adult Man, ICRP Publication 20. Pergamon, Oxford.

ICRP (1977). Recommendations of the International Commission on Radiological Protection, ICRP Publication 26. Pergamon, Oxford.

ICRP (1978). Statement from the 1978 Stockholm Meeting of the ICRP, ICRP Publication 28. Pergamon, Oxford.

ICRP (1979). Limits for Intakes of Radionuclides by Workers, ICRP Publication 30: Part 1. Pergamon, Oxford.

ICRP (1980). Limits for Intakes of Radionuclides by Workers, ICRP Publication 30: Part 2. Pergamon, Oxford.

ICRP (1981). Limits for Intakes of Radionuclides by Workers, ICRP Publication 30: Part 3. Pergamon, Oxford.

ICRP (1987). Protection of the Patient in Nuclear Medicine, ICRP Publication 52. Pergamon, Oxford.

ICRU (1979). Methods of Assessment of Absorbed Dose in Clinical Use of Radionuclides, ICRU Report 32. International Commission on Radiation Units and Measurements, Bethesda, Maryland.

Johansson L. Mattsson S. Carlsson S. (1981a). Effective dose equivalent from long-lived radionuclide impurities in Tc-99m-pertechnetate. In: Third International Radiopharmaceutical Dosimetry Symposium (Proc. Conf. Oak Ridge, Tennessee, 1980), HHS Publication (FDA 81–8166), pp. 602–615. Department of Health and Human Services, Bureau of Radiological Health, Rockville, Maryland.

Johansson L. Mattsson S. Nosslin B. (1981b). Radiation Doses from Radioactive Substances in Medical Use. Swedish National Institute of Radiation Protection, Stockholm. (In Swedish with an English word list).

Kaul A. Oeff K. Roedler H. D. Vogelsang T. (1973a). Radiopharmaceuticals—Biokinetic Data and Results of Radiation Dose Calculations. Informationsdienst für Nuklearmedizin, Berlin.

Kaul A. Oeff K. Roedler H. D. Vogelsang T. (1973b). Die Strahlenbelastung von Patienten bei der nuklear-medizinischen Anwendung offener radioaktiver Stoffe. Informationsdienst für Nuklearmedizin, Berlin.

Kaul A. Hinz G. Kossel F. König K. Kragh P. Nitschke J. Roedler H. D. Schwarz E. R. (1984). The Effective per Caput Dose Equivalent as a Measure of Medical Radiation Exposure of the Population—A Complement or an Alternative to the Genetically Significant Dose? ISH Report 52. Institut für Strahlenhygiene des Bundesgesundheit-samtes, Neuherberg, Federal Republic of Germany.

Kaul A. Krauss O. Petrausch G. (1985). Strahlenexposition durch Tc-99m-Methylendiphosphonat—lokale Dosisverteilung in Wachstum szonen des kindlichen Skeletts und Organdosen. In: Medizinische Physik 1985. ( Poretti G. ed.). Deutsche Gesellschaft fur medizinische Physik, Bern, Switzerland.

Loevinger R. Berman M. (1968). A schema for absorbed-dose calculations for biologically distributed radionuclides. Medical International Radiation Dose Committee (MIRD) Pamphlet No. 1. J. Nucl. Med. 9, Suppl. 1, 7–14.

NCRP (1982). Nuclear Medicine—Factors Influencing the Choice and Use of Radionuclides in Diagnosis and Therapy, NCRP Report No. 70. National Council on Radiation Protection and Measurements, Bethesda, Maryland.

NCRP (1985a). The Experimental Basis for Absorbed-Dose Calculations in Medical Uses of Radionuclides, NCRP Report No. 83. National Council on Radiation Protection and Measurements, Bethesda, Maryland.

NCRP (1985b). General Concepts for the Dosimetry of Internally Deposited Radionuclides, NCRP Report No. 84. National Council on Radiation Protection and Measurements, Bethesda, Maryland.

Roedler H. D. (1981). Accuracy of internal dose calculations with special consideration of radiopharmaceutical biokinetics. In: Third International Radiopharmaceutical Dosimetry Symposium (Proc. Conf. Oak Ridge, Tennessee, 1980), HHS Publication (FDA 81–8166). Department of Health and Human Welfare, Bureau of Radiological Health, Rockville, Maryland.

Roedler H. D. Kaul A. (1976). Dose to target organs from remaining body activity: Results of the formally exact and approximate solution. In: Radiopharmaceutical Dosimetry Symposium (Proc. Conf. Oak Ridge, Tennessee, April 1976), HEW Publication (FDA 76–8044), pp. 155–163. Department of Health, Education and Welfare, Bureau of Radiological Health, Rockville, Maryland.

Roedler H. D. Kaul A. Berner W. Koeppe P. Glaubitt D. (1972). Development of an extended formalism for internal dose calculations and practical applications to several biologically distributed radioelements. In: Assessment of Radioactive Contamination in Man (Proc. Symp. Stockholm, 1971), pp. 515–541. International Atomic Energy Agency, Vienna, Austria.

Roedler H. D. Kaul A. Hine G. J. (1978). Internal Radiation Dose in Diagnostic Nuclear Medicine. Hoffman, Berlin.

Snyder W. S. Ford M. R. Warner G. G. Fisher H. R. Jr (1969). Estimates of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. Medical Internal Radiation Dose Committee (MIRD) Pamphlet No. 5. J. Nucl. Med. 10, Suppl. 3.

Snyder W. S. Ford M. R. Warner G. G. Watson S. B. (1974). A Tabulation of Dose-equivalent per Microcurie-day for Source and Target Organs of an Adult for Various Radionuclides, Report ORNL-5000. Oak Ridge National Laboratory, Tennessee; National Technical Information Service, Springfield, Virginia.

Snyder W. S. Ford M. R. Warner G. G. Watson S. B. (1975). “S” Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs, Medical Internal Radiation Dose Committee (MIRD) Pamphlet No. 11. Available from Society of Nuclear Medicine, 475 Park Avenue South, New York, NY 10016, USA.

Snyder W. S. Ford M. R. Warner G. G. (1978). Estimates of Specific Absorbed Fractions for Photon Sources Uniformly Distributed in Various Organs of a Heterogeneous Phantom, Medical Internal Radiation Dose Committee (NM/MIRD) Pamphlet No. 5, revised. Available from Society of Nuclear Medicine, 475 Park Avenue South, New York, NY 10016, USA.

Winchell H. S. Horst W. D. Braum L. (1980). N-isopropyl (¹²³I)p-iodoamphetamine: Single-pass brain uptake and washout; binding to brain synaptosomes; and localisation in the dog and monkey brain. J. Nucl. Med. 21, 947–952.

WHO (1982). Quality Assurance in Nuclear Medicine. World Health Organisation, Geneva.

WHO (1986). Review of Quality Control in Nuclear Medicine, bga-Schrifter 8/1986. ( Cradduck T. D. Busemann-Sokole E. Roedler H. D. eds) MMV Verlag, Munich.

Cristy M. (1980). Mathematical Phantoms Representing Children of Various Ages for Use in Estimates of Internal Dose, Report ORNL/NUREG/TM-367. Oak Ridge National Laboratory, Tennessee.

ICRP (1975). Reference Man: Anatomical, Physiological and Metabolic Characteristics, ICRP Publication 23. Pergamon, Oxford.

Snyder W. S. Ford M. R. Warner G. G. Watson S. B. (1975). “S” Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs, Medical Internal Radiation Dose Committee (MIRD) Pamphlet No. 11. Available from the Society of Nuclear Medicine, 475 Park Avenue South, New York, NY 10016, USA.

Charkes N. D. Makler P. T. Jr Philips C. (1978). Studies of skeletal tracer kinetics. I. Digital-computer solution of a five compartment model of [¹⁸F] fluoride kinetics in humans. J. Nucl. Med. 19, 1301–1309.

Cloutier R. J. Watson E. E. (1970). Radiation dose from radioisotopes in the blood. In: Medical Radionuclides: Radiation Dose and Effects, pp. 325–346. ( Cloutier R. J. Edwards C. E. Snyder W. S. , eds) National Technical Information Service, Springfield, Virginia. Report No. CONF 691212.

Huchzermeyer H. Schmitz-Feurerhake I. Reblin T. (1977). Determination of splenic blood flow by inhalation of radioactive rare gases. Eur. J. Clin. Invest. 7, 345–349.

Hughes Jones N. C. Mollison P. L. Veall N. (1957). Removal of incompatible red cells by the spleen. Br. J. Haematol. 3, 125–133.

ICRP (1975). Reference Man: Anatomical, Physiological and Metabolic Characteristics, ICRP Publication 23. Pergamon, Oxford.

Lahtinen T. Alhava E. M. Karjalainen P. Romppanen T. (1981). The effect of age on blood flow in the proximal femur in man. J. Nucl. Med. 22, 966–972.

Lahtinen R. Lahtinen T. Romppanen T. (1982). Bone and bone-marrow blood flow in chronic granulocytic leukemia and primary myelofibrosis. J. Nucl. Med. 23, 218–224.

Lahtinen R. Lahtinen T. Hyödynmaa S. (1983). Increased bone marrow blood flow in polycythemia vera. Eur. J. Nucl. Med. 3, 19–22.

Peters A. M. Klonizakis I. Lavender J. P. Lewis S. M. (1980). Use of ¹¹¹Indium-labelled platelets to measure spleen function. Br. J. Haematol. 46, 587–593.

Peters A. M. Walport M. J. Bell R. N. Lavender J. P. (1984). Methods of measuring splenic blood flow and platelet transit time with In-111-labelled platelets. J. Nucl. Med. 25, 86–90.

Simon J. Guiraud R. Geral J. P. (1977). Comparative study of ⁹⁹Tc^m pertechnetate and ¹³¹I-iodoantipyrine in the determination of bone blood flow. Int. J. Nucl. Med. Biol. 4, 231–232.

Spector W. S. (1956). Handbook of Biological Data. Saunders, Philadelphia.

Tondevold E. Eliasen P. (1982). Blood flow rates in canine cortical and cancellous bone measured with ^99mTc-labelled human albumin microspheres. Acta Orthop. Scand. 53, 7–11.

Williams R. Condon R. E. Williams H. S. Blendis L. M. Kreel L. (1968). Splenic blood flow in cirrhosis and portal hypertension. Clin. Sci. 34, 441–452.

Wootton R. (1974). The single-passage extraction of ¹⁸F in rabbit bone. Clin. Sci. Mol. Med. 47, 73–77.

Wootton R. Reeve J. Veall N. (1976). The clinical measurement of skeletal blood flow. Clin. Sci. Mol. Med. 50, 261–268.

Corazziari E. Cucchiara S. Staiano A. Romaniello G. Tamburrini O. Torsoli A. Auricchio S. (1985). Gastrointestinal transit time, frequency of defecation, and anorectal manometry in healthy and constipated children. J. Pediat. 106, 379–382.

ICRP (1979). Limits for Intakes of Radionuclides by Workers, ICRP Publication 30: Part 1. Pergamon, Oxford.

Siegel J. A. Wu R. K. Knight L. C. Zelac R. E. Stern H. S. Malmud L. S. (1983). Radiation dose estimates for oral agents used in upper gastrointestinal disease. J. Nucl. Med. 24, 835–837.

Smith T. Veall N. Wootton R. (1982). Bladder wall dose from administered radiopharmaceuticals: The effect of variation in urine flow rate, voiding interval and initial bladder content. Radiat. Prot. Dosim. 2, 183–189.

Snyder W. S. Ford M. R. (1976). Estimation of doses to the urinary bladder and to the gonads. In: Radiopharmaceutical Dosimetry Symp. (Proc. Conf. Oak Ridge, Tennessee, April 1976), HEW Publication (FDA 76–8044), pp. 313–349. Department of Health, Education and Welfare, Bureau of Radiological Health, Rockville, Maryland.

Syed I. B. (1976). Dosimetry of indium-113m radiopharmaceuticals with special attention to the urinary bladder. In: Radiopharmaceutical Dosimetry Symp. (Proc. Conf. Oak Ridge, Tennessee, April 1976), HEW Publication (FDA 76–8044), pp. 306–369. Department of Health, Education and Welfare, Bureau of Radiological Health, Rockville, Maryland.

De Nardo G. L. Jacobson S. J. Raventos A. (1972). ⁸⁵Sr bone scan in neoplastic disease. Semin. Nucl. Med. 2, 18–30.

ICRP (1973). Alkaline Earth Metabolism in Adult Man, ICRP Publication 20. Pergamon, Oxford.

ICRP (1977). Recommendations of the ICRP, ICRP Publication 26. Pergamon, Oxford.

ICRP (1979). Limits for Intakes of Radionuclides by Workers, ICRP Publication 30. Pergamon, Oxford.

Johansson L. (1981). S-values for bone surfaces with a source distributed homogeneously in bone volume or with a surface deposited source. In: Third International Radiopharmaceutical Dosimetry Symposium (Proc. Conf. Oak Ridge Tennessee. October, 1980), HHS Publication (FDA 81–8166), pp. 554–562. Department of Health and Human Services, Bureau of Radiological Health, Rockville, Maryland.

Merrick M. V. (1975). Review article: Bone scanning. Br. J. Radiol. 48, 327–351.

Scheer K. E. Harbst H. Kampman H. zum Winkel K. Maier-Borst W. Lorenz W. J. Bilaniuk L. (1969). Bone scintigraphy with ¹⁸F and ⁸⁷Sr^m. Medical Radioisotope Scintigraphy (Proc. Symp. Salzburg, 1968), Vol. 2, pp. 325–337. International Atomic Energy Agency, Vienna, Austria.

Herzog H. Spohr G. Notohamiprodjo G. Feinendegen L. E. (1984). Biokinetics of Tc-99m-marked RES-radiopharmaceuticals. In: Nuklearmedizin, 21st Int. Annu. Meeting Soc. Nucl. Med. Europe. Ulm 1983, pp. 492–493. Schattauer, Stuttgart.

MIRD (1975a). Medical Internal Radiation Dose Committee Estimate Report No. 3. Summary of current radiation dose estimates to humans with various liver conditions from ^99mTc-sulfur colloid. J. Nucl. Med. 16, 108A–108B.

MIRD (1975b). Medical Internal Radiation Dose Committee Estimate Report No. 4. Summary of current radiation dose estimates to humans with various liver conditions from ¹⁹⁸Au-colloidal gold. J. Nucl. Med. 16, 173–174.

Brown P. H. Krishnamurthy G. T. Bobba V. R. Kingston E. (1981). Radiation-dose calculation for Tc-99m HIDA in health and disease. J. Nucl. Med. 22, 177–183.

Brown P. H. Krishnamurthy G. T. Bobba V. R. Kingston E. Turner F. E. (1982). Radiation-dose calculation for five Tc-99m IDA hepatobiliary agents. J. Nucl. Med. 23, 1025–1030.

Galli G. Maini C. L. Troncone L. (1979). Study of hepatocyte function using radiotracers. In: Principles of Radiopharmacology III, pp. 159–178. ( Colombetti L. G. ed.) CRC Press, Boca Raton, Florida.

Gelius L. Skretting A. Aas M. (1981). A mathematical model for the liver uptake and excretion of ^99mTc-diethyl IDA. Eur. J. Nucl. Med. 6, 139–142.

Koutoulidis C. Chiotellis E. Lymberis C. (1979). Absorbed dose estimation of some ^99mTc-hepatobiliary agents. Eur. J. Nucl. Med. 4, 441–444.

MIRD (1975). Medical Internal Radiation Dose Committee. Estimate Report No. 7. Summary of current radiation dose estimates to humans from 123-I, 124-I, 125-I, 126-I, 130-I and 131-I as Sodium Rose Bengal. J. Nucl. Med. 16, 1214–1217.

Ryan J. Cooper M. Loberg M. Harvey E. Sikorski S. (1977). Technetium-99m-labelled N-(2,6-dimethylphenyl carbamoylmethyl)-iminodiacetic acid (Tc^99mHIDA): A new radiopharmaceutical for hepatobiliary imaging studies. J. Nucl. Med. 18, 997–1004.

Taavitsainen M. Riihimäki E. Tähti E. (1980). Body disappearance and liver mean transit time of 99m-Tc-diethyl-IDA. Eur. J. Nucl. Med. 5, 147–150.

Venot A. Grandjouan S. Steimer J. L. Mallet A. Roucayrol J. C. (1980). Improvement of dynamic cholescintigraphy through mathematical modelling of Tc-99m-diethyl-IDA pharmacokinetics. In: INSERM Colloquium, Vol. 88, pp. 459–468. INSERM, Paris.

Wistow B. W. Subramanian G. van Heertum R. L. (1977). An evaluation of ^99mTc labelled hepatobiliary agents. J. Nucl. Med. 18, 455–461.

Wu R. K. Siegel J. A. Rattner Z. Malmud L. S. (1984). Tc-99m HIDA dosimetry in patients with various hepatic disorders. J. Nucl. Med. 25, 905–912.

Brookeman V. A. Morin R. L. (1975). Dosimetry of several DTPA radiopharmaceuticals in cisternography. J. Nucl. Med. 16, 1177–1182.

DeLand F. H. Simmons G. H. (1976). Spinal cord and cerebrospinal fluid. In: Radiopharmaceutical Dosimetry Symposium (Proc. Conf. Oak Ridge, Tennessee, April 1976), HEW Publication (FDA 76–8044), pp. 390–403. US Department of Health, Education and Welfare Bureau of Radiological Health, Rockville, Maryland.

Goodwin D. A. Song C. H. Finsto R. Matin P. (1973). Preparation, physiology and dosimetry of ¹¹¹In-labelled radiopharmaceuticals for cisternography. Radiology 108, 91–98.

Harbert J. C. Zeiger L. S. (1970). Radiation dose in encephalography. Lancet i, 954–955.

Harbert J. C. Reed V. McCullogh D. C. (1973). Comparison between ¹³¹I-IHSA and ¹⁶⁹Yb-DTPA for cisternography. J. Nucl. Med. 14, 765–768.

Harbert J. C. McCullogh D. C. Zeiger L. S. Davidson J. D. Ashburn W. L. (1970). Spinal cord dosimetry in ¹³¹I-IHSA cisternography. J. Nucl. Med. 11, 534–541.

Hilditch T. E. (1968). Radiation dose in isotope encephalography. Lancet ii, 573–574.

ICRP (1975). Reference Man: Anatomical, Physiological and Metabolic Characteristics, ICRP Publication 23. Pergamon, Oxford.

Jahns E. Zeidler U. Mariss P. Patzoldt U. (1976). Strahlenbelastung bei der Cisternoszintigraphie mit 169-Yb-DTPA. Nuklearmedizin (Proc. 14th Int. Meeting, Berlin, 1976), pp. 317–319 (in German).

Johnston R. E. Staab E. V. Brill A. B. Allen J. H. (1972). Radiation dosimetry associated with the intrathecal administration of ¹³¹I human serum albumin. Br. J. Radiol. 45, 444–451.

McEwan A. C. (1975). Radiation dosimetry of Yb-169 DTPA in cisternography. Aust. Radiol. 19, 8–14.

Morin R. L. Brookeman V. A. (1974). ¹⁶⁹Yb-DTPA distribution and dosimetry in cisternography. J. Nucl. Med. 15, 786–796.

Oster Z. H. Som P. Gil M. C. Fairchild R. G. Goldman A. G. Schachner E. R. Sacker D. F. Atkins H. L. Meinken G. E. Srivastava S. C. Richards P. Brill A. B. (1981). Ruthenium-97 DTPA: A new radiopharmaceutical for cisternography. J. Nucl. Med. 22, 269–273.

Partain C. L. Alderson P. O. Donovan R. L. Siegal B. A. Rujanavech N. Johnston R. E. Staab V. E. (1976). Regional kinetics of Indium 111-DTPA in CSF imaging of normal volunteers. In: Radiopharmaceutical Dosimetry Symposium (Proc. Conf. Oak Ridge, Tennessee, April 1976), HEW Publication (FDA 76–8044), pp. 404–422. Department of Health, Education and Welfare, Rockville, Maryland.

Partain C. L. Alderson P. O. Siegel B. A. (1974). A mathematical model for radiopharmaceutical kinetics in cisternography. J. Nucl. Med. 15, 521–522 (abstract).

Rauber-Kopsch . (1943). Lehrbuch und Atlas der Anatomie des Menschen, Band III. G. Thieme, 1943, p. 21 (in German).

Som P. Hosain F. Wagner H. N. Jr (1971). Kinetics of agents used for cisternography. J. Nucl. Med. 12, 396 (abstract).

Smith P. H. S. Thomas P. R. M. Steere H. A. Beatty H. E. Dawson K. B. Peckham M. J. (1976). Therapeutic irradiation of the central nervous system using intrathecal ⁹⁰Y-DTPA. Br. J. Radiol. 49, 141–147.

Bigler R. E. Sgouros G. (1983). Biological analysis and dosimetry for ¹⁵O-labelled O₂, CO₂ and CO gases administered continuously by inhalation. J. Nucl. Med. 24, 431–437.

Kearfott K. J. (1982). Absorbed dose estimates for positron emission tomography (PET): C¹⁵O, ¹¹CO and CO¹⁵O. J. Nucl. Med. 23, 1031–1037.

Bergqvist L. Strand S.-E. Persson B. Hafström L. Jönsson P.-E. (1982). Dosimetry in lymphoscintigraphy of Tc-99m antimony sulfide colloid. J. Nucl. Med. 23, 698–705.

Bronskill M. J. (1983). Radiation dose estimates for interstitial lymphoscintigraphic agents. Semin. Nucl. Med. 13, 20–25.

Cristy (1980). Mathematical Phantoms Representing Children of Various Ages for Use in Estimates of Internal Dose, Report ORNL/NUREG/TM-367. Oak Ridge National Laboratory, Oak Ridge, Tennessee.

Ellet W. H. Humes R. J. (1971). Absorbed fractions for small volumes containing photon emitting radioactivity. Medical Internal Radiation Dose Committee (MIRD) Pamphlet No. 8. J. Nucl. Med. 12, Suppl. No. 5, 27–32.

Lathrop K. A. Atkins H. L. Berman M. Hays M. T. Smith E. M. (1976). Summary of current radiation dose estimates to normal humans from Tc-99m as sodium pertechnetate. Medical Internal Radiation Dose Committee (MIRD) Dose Estimate Report No. 8. J. Nucl. Med. 17, 74–77.

Roedler H. D. (1987). Assessment of fetal activity concentration and fetal dose for selected radionuclides based upon animal and human data. In: Age-related Factors in Radionuclide Metabolism and Dosimetry ( Gerber G. B. Metivier H. Smith H. eds) Proc. Symp. CEC Angers 1986, pp. 327–338. Martinus Nijhoff, Dordrecht.

Winkel zum K. Hermann H. J. (1977). Scintigraphy of lymph nodes. Lymphology 10, 107–114.

Bates D. V. (1952). The uptake of carbon monoxide in health and in emphysema. Clin. Sci. 11, 21–32.

Kearfott K. J. (1982). Absorbed dose estimates for positron emission tomography (PET): C¹⁵O, ¹¹CO and CO¹⁵O. J. Nucl. Med. 23, 1031–1037.

West J. B. Holland R. A. B. Dollery C. T. Matthews C. M. E. (1962). Interpretation of radioactive gas clearance rates in the lung. J. Appl. Physiol. 17, 14–20.

Kenny P. J. Watson D. D. Janowitz M. D. Finn R. D. Gilson A. J. (1976). Dosimetry of some accelerator produced radioactive gases. In: Proc. Second Int. Radiopharmaceutical Dosimetry Symposium, Oak Ridge, Tennessee (FDA 76–8044), pp. 475–487. Bureau of Radiological Health, Rockville, Maryland.

West J. B. Dollery C. T. (1962). Uptake of oxygen-15-labeled CO₂ compared with carbon-11-labeled CO₂ in the lung. J. Appl. Physiol. 17, 9–13.

West J. B. Holland R. A. B. Dollery C. T. Matthews C. M. E. (1962). Interpretation of radioactive gas clearance rates in the lung. J. Appl. Physiol. 17, 14–20.

Marlow C. G. Sheppard G. (1970). Labelled tracers of inulin for physiological measurements. Clin. Chim. Acta 28, 469–478.

Sziklas J. J. Hosain F. Reba R. C. Wagner H. N. (1971). Comparison of ¹⁶⁹Yb-DTPA, ^113mIn-DTPA, ¹⁴C-inulin and endogenous creatinine to estimate glomerular filtration. J. Nucl. Biol. Med. 15, 122–125.

Rosenzweig D. Y. Hughes J. M. B. Jones T. (1969/70). Uneven ventilation within and between regions of the normal lung measured with nitrogen-13. Resp. Physiol. 8, 86–97.

Senda M. Murata K. Itoh H. Yonekura Y. Torizuka K. (1986). Quantitative evaluation of regional pulmonary ventilation using PET and nitrogen-13 gas. J. Nucl. Med. 27, 268–273.

Hughes J. M. B. (1979). Short-life radionuclides and regional lung function. Br. J. Radiol. 52, 353–370.

Lockwood A. H. (1980). Absorbed doses of radiation after an intravenous injection of N-13 ammonia in man. J. Nucl. Med. 21, 276–278.

Lockwood A. H. McDonald J. M. Reiman R. E. Gelbard A. S. Laughlin J. S. Duffy T. E. Plum F. (1979). The dynamics of ammonia metabolism in man: Effects of liver disease and hyperammonemia. J. Clin. Invest. 63, 449–460.

Cooper A. J. L. Gelbard A. S. Freed B. R. (1985). Nitrogen-13 as a biochemical tracer. In: Advances in Enzymology, pp. 251–356. ( Meister A. , ed.) Advances in Enzymology, Wiley, New York.

Gelbard A. S. Benua R. S. McDonald J. M. Reiman R. E. Vomero J. J. Laughlin J. S. (1979). Organ imaging with N-13-L-glutamate. J. Nucl. Med. 20, 663.

Gelbard A. S. Benua R. S. Reiman R. E. McDonald J. M. Vomero J. J. Laughlin J. S. (1980). Imaging of the human heart after administration of L-(N-13) glutamate. J. Nucl. Med. 21, 988–991.

Knapp W. H. Helus F. Ostertag H. Tillmanns H. Kübler W. (1982). Uptake and turnover of L-(¹³N)-glutamate in the normal human heart and in patients with coronary artery disease. Eur. J. Nucl. Med. 7, 211–215.

Knapp W. H. Helus F. Sinn H. Ostertag H. Georgi P. Brandeis W. E. Braun A. (1984). N-13 L-glutamate uptake in malignancy: Its relationship to blood flow. J. Nucl. Med. 25, 989–997.

Kubota K. Fukuda H. Yamada K. Endo S. Ito M. Abe Y. Yamaguchi T. Fujiwara T. Sato T. Yamaura H. Matsuzawa T. Ishiwata K. Iwata R. Ido T. (1983). Experimental pancreas imaging study with ¹³N-glutamate using positron computer tomography. Eur. J. Nucl. Med. 8, 528–530.

Bigler R. E. Sgouros G. (1983). Biological analysis and dosimetry for ¹⁵O-labelled O₂, CO₂ and CO gases administered continuously by inhalation. J. Nucl. Med. 24, 431–437.

Bigler R. E. Kostick J. A. Gillespie J. R. (1981). Compartmental analysis of the steady-state distribution of ¹⁵O₂ and H₂¹⁵O in total body. J. Nucl. Med. 22, 959–965.

Bigler R. E. Sgouros G. (1983). Biological analysis and dosimetry for ¹⁵O-labelled O₂, CO₂ and CO gases administered continuously by inhalation. J. Nucl. Med. 24, 431–437.

Dollery C. T. Heimburg P. Hugh-Jones P. (1962). The relationship between blood flow and clearance rate of radioactive carbon dioxide and oxygen in normal and oedematous lungs. J. Physiol. 162, 93–104.

Kearfott K. J. (1982). Absorbed dose estimates for positron emission tomography (PET): C¹⁵O, ¹¹CO and CO¹⁵O. J. Nucl. Med. 23, 1031–1037.

Kenny P. J. Watson D. D. Janowitz M. D. Finn R. D. Gilson A. J. (1976). Dosimetry of some accelerator produced radioactive gases. In: Proc. Second Int. Radiopharmaceutical Dosimetry Symposium, Oak Ridge, Tennessee, (FDA 76–8044), pp. 475–487. Oak Ridge National Laboratories, Oak Ridge, Tennessee.

Altman P. L. Dittmer D. S. (1971). In: Respiration and Circulation. Federation of American Societies for Experimental Biology, Bethesda, Maryland.

Bigler R. E. Kostick J. A. Gillespie J. R. (1981). Compartmental analysis of the steady-state distribution of ¹⁵O₂ and H₂¹⁵O in total body. J. Nucl. Med. 22, 959–965.

Bigler R. E. Sgouros G. (1983). Biological analysis and dosimetry for ¹⁵O-labelled O₂, CO₂ and CO gases administered continuously by inhalation. J. Nucl. Med. 24, 431–437.

Kearfott K. J. (1982). Absorbed dose estimates for positron emission tomography (PET): C¹⁵O, ¹¹CO and CO¹⁵O. J. Nucl. Med. 23, 1031–1037.

West J. B. Holland R. A. B. Dollery C. T. Matthews C. M. E. (1962). Interpretation of radioactive gas clearance rates in the lung. J. Appl. Physiol. 17, 14–20.

Blau M. Ganatra R. Bender M. A. (1972). ¹⁸F-fluoride for bone imaging. Semin. Nucl. Med. 2, 31–37.

Charkes N. D. Makler P. T. Philips C. (1978). Studies of skeletal tracer kinetics. 1. Digital-computer solution of a five-compartment model of (¹⁸F) fluoride kinetics in humans. J. Nucl. Med. 19, 1301–1309.

Wootton R. Reeve J. Veall N. (1976). The clinical measurement of skeletal blood flow. Clin. Sci. Mol. Med. 50, 261–268.

Gallagher B. M. Ansari A. Atkins H. Casella V. Christman D. R. Fowler J. S. Ido T. MacGregor R. R. Som P. Wan C. N. Wolf A. P. Kuhl D. E. Reivich M. (1977). Radiopharmaceuticals XXVII: ¹⁸F-labelled 2-deoxy-2-fluoro-D-glucose metabolism in vivo: Tissue distribution and imaging studies in animals. J. Nucl. Med. 18, 990–996.

Jones S. C. Alavi A. Christman D. Montanez I. Wolf A. P. Reivich M. (1982). The radiation dosimetry of 2-F-18 fluoro-2-deoxy-D-glucose in man. J. Nucl. Med. 23, 613–617.

Phelps M. E. Hoffman E. J. Selin C. Huang S. C. Robinson G. MacDonald N. Schelbert H. Kuhl D. E. (1978). Investigation of ¹⁸F 2-fluoro-2-deoxyglucose for the measure of myocardial glucose metabolism. J. Nucl. Med. 19, 1311–1319.

ICRP (1980). Limits for Intakes of Radionuclides by Workers, ICRP Publication 30: Part 2. Pergamon, Oxford.

Henningsen N. C. Ohlsson O. Mattsson S. Nosslin B. (1982). Whole body measurements of sodium turn-over in offspring of patients with sustained essential hypertension. Eur. J. Nucl. Med. 7, 225–228.

Vennart J. (1963) External counting. In: Diagnosis and Treatment of Radioactive Poisoning, STI/PUB 65 (IAEA, 1963), pp. 3–22. International Atomic Energy Agency, Vienna, Austria.

ICRP (1975). Report of the Task Group on Reference Man, ICRP Publication 23. Pergamon, Oxford.

Kniffen J. C. Roessler C. E. Roessler G. S. Dunavant B. G. Quick D. T. (1970). Whole-body counter determination of ²⁸Mg retention in humans. In: Radioaktive Isotope in Klinik und Forschung, Vol. 9, pp. 231–232. ( Fellinger K. Höfer R. eds) Urban and Schwarzenberg, München.

Roessler G. M. S. (1972). Whole-body retention and excretion of magnesium in humans. Ph.D. Thesis, University of Florida, Mf-order No. 73965.

Shils M. E. (1973). Magnesium, Chapter 6, Part B. In: Modern Nutrition in Health and Disease—Dietotherapy, 5th edn. ( Goodhart R. S. Shils M. E. eds) Lea and Febiger, Philadelphia.

ICRP (1979). Limits for Intakes of Radionuclides by Workers, ICRP Publication 30: Part 1. Pergamon, Oxford.

ICRP (1980). Limits for Intakes of Radionuclides by Workers, ICRP Publication 30: Part 2. Pergamon, Oxford.

ICRP (1980). Limits for Intake of Radionuclides by Workers, ICRP Publication 30: Part 2. Pergamon, Oxford.

Gehring P. J. Hammond P. B. (1967). The interrelationship between thallium and potassium in animals. J. Pharmac. Exp. Ther. 155, 187–201.

Kearfott K. J. (1982). Radiation absorbed dose estimates for positron emission tomography (PET): K-38, Rb-81, Rb-82, and Cs-130. J. Nucl. Med. 23, 1128–1132.

Sapirstein L. A. (1958). Regional blood flow by fractional distribution of indicators. Am. J. Physiol. 193, 161–168.

Spector W. S. (1956). Handbook of Biological Data, W. B. Saunders, Philadelphia.

Forbes G. B. Lewis A. M. (1956). Total sodium, potassium and chloride in adult man. J. Clin. Invest. 35, 596–600.

ICRP (1959). Report of Committee II on Permissible Dose for Internal Radiation, ICRP Publication 2. Pergamon, Oxford.

ICRP (1980). Limits for Intakes of Radionuclides by Workers, ICRP Publication 30: Part 2. Pergamon, Oxford.

Kaul A. Oberhausen E. Roedler H. D. Werner E. (1974). Interne Strahlenexposition durch ⁴⁰K. In: Die natürliche Strahlenexposition des Menschen. ( Aurand K. , eds) Georg Thieme Verlag, Stuttgart.

Leggett R. W. Williams L. R. (1986). A model for the kinetics of potassium in healthy humans. Phys. Med. Biol. 31, 23–42.

Oberhausen E. (1963). Die Altersabhängigkeit des Kalium- und Cesium-137-Gehaltes des Menschen. Biophysik 1/2, 135–142.

Sapirstein L. A. (1958). Regional blood flow by fractional distribution of indicators. Am. J. Physiol. 193, 161–168.

Harrison G. E. Carr T. E. F. Sutton A. (1967). Distribution of radioactive calcium, strontium, barium and radium following intravenous injection into a healthy man. Int. J. Rad. Biol. 13, 235–247.

ICRP (1972). Alkaline Earth Metabolism in Adult Man, ICRP Publication 20. Pergamon, Oxford.

ICRP (1979). Limits for Intakes of Radionuclides by Workers, ICRP Publication 30: Part 1. Pergamon, Oxford.

Ditchburn R. K. Smith A. H. Hayter C. J. (1974). The assessement of fat absorption in man utilizing single stools or incomplete faecal collections after oral administration of radioactive triolein with an unabsorbed radioactive marker. Int. J. App. Rad. Isotopes 25, 167–176.

Pearson J. D. (1966). Use of Cr⁵¹-labelled haemoglobin and Sc⁴⁷ as inert faecal markers. Int. J. Appl. Radiat. 17, 13–16.

Ogg C. S. Pearson J. D. Veall N. (1968). A method for measuring the gastro-intestinal absorption of ⁴⁷Ca using ⁴⁷Sc as an inert marker. Clin. Sci. 34, 327–332.

Lim T. H. (1978). Kinetic Model Building Using Advanced Nuclear Medicine Techniques—The Kinetics of Chromium (III) in the Human Body, Report LBL 7473. Lawrence Berkeley Laboratory, University of California. (June 1978).

Bjarnason I. Peters T. J. Veall N. (1983). A persistent defect in intestinal permeability in coeliac disease demonstrated by a ⁵¹Cr-labelled EDTA absorption test. Lancet i, 323–325.

Bröchner-Mortensen J. Giese J. Rossing N. (1969). Renal inulin clearance versus total plasma clearance of ⁵¹Cr-EDTA. J. Lab. Clin. Invest. 23, 301–305.

Chantler C. Garnett E. S. Parsons V. Veall N. (1969). Glomerular filtration rate measurement in man by the single injection method using ⁵¹Cr-EDTA. Clin. Sci. 37, 169–180.

O'Reilly P. H. Shields R. A. Testa H. J. (1979). Nuclear Medicine in Urology and Nephrology. Butterworths, London.

Belcher E. H. Hughes Jones N. C. (1960). The mathematical analysis of ⁵¹Cr deposition in organs following the injection of ⁵¹Cr-labelled red cells. Clin. Sci. 19, 657–663.

Hughes Jones N. C. Szur L. (1957). Determination of the sites of red-cell destruction using ⁵¹Cr-labelled cells. Br. J. Haematol. 3, 320–331.

ICRU (1979). Methods of Assessment of Absorbed Dose in Clinical Use of Radionuclides, ICRU Report 32. International Commission on Radiation Units, Washington, DC.

Lim T. H. (1978). Kinetic Model Building Using Advanced Nuclear Medicine Techniques—The Kinetics of Chromium (III) in the Human Body, Report LBL 7473. Lawrence Berkeley Laboratory, University of California.

Roth P. Werner E. Henrichs K. Elsasser U. Kaul A. (1986). Variations in absorbed dose from ⁵¹Cr: Investigations with labelled erythrocytes. In: Fourth Int. Radiopharmaceutical Dosimetry Symposium, Oak Ridge 1985, Oak Ridge Assoc. Univ. CONF-851113, pp. 673–680. Oak Ridge National Laboratories, Oak Ridge, Tennessee.

Schloesser L. L. Korst D. R. Clatanoff D. V. Schilling R. F. (1957). Radioactivity over the spleen and liver following the transfusion of chromium⁵¹-labelled erythrocytes in hemolytic anemia. J. Clin. Invest. 36, 1470–1485.

Atkins H. L. Goldman A. G. Fairchild R. G. Oster Z. H. Som P. Richards P. Meinken G. E. Srivastava S. C. (1980). Splenic sequestration of ^99mTc labelled, heat-treated red blood cells. Radiology 136, 501–503.

Lim T. H. (1978). Kinetic Model Building Using Advanced Nuclear Medicine Techniques—The Kinetics of Chromium (III) in the Human Body, Report LBL 7473. Lawrence Berkeley Laboratory, University of California.

Smith P. H. S. (1974). ⁹⁹Tc^m labelled erythrocytes for spleen scanning. Int. J. Appl. Radiat. Isot. 25, 137–139.

Spinelli-Ressi F. (1964). In: Medical Radioisotope Scanning, Vol. II, pp. 355–369. International Atomic Energy Agency, Vienna.

Williams E. D. Ahuja S. Szur L. Lewis S. M. Glass H. I. (1972). Rate of loss of ⁵¹Cr from the spleen. J. Nucl. Med. 13, 686–687.

McMillan R. Scott J. L. (1968). Leukocyte labeling with ⁵¹Chromium. I. Technique and results in normal subjects. Blood 32, 738–754.

Donaldson R. M. Jr Barreras R. F. (1966). Intestinal absorption of trace quantities of chromium. J. Lab. Clin. Med. 68, 484–493.

Griffith G. H. Owen G. M. Kirkman S. Shields R. (1966). Measurement of rate of gastric emptying using Chromium-51. Lancet i, 1244–1245.

Hansky J. Connell A. M. (1962). Measurement of gastrointestinal transit using radioactive chromium. Gut 3, 187–188.

Adopted model.

Atkins H. L. Som P. Fairchild R. G. Hui J. Schachner E. Goldman A. Ku T. (1979). Myocardial positron tomography with Manganese-52m. Radiology 133, 769–774.

Mahoney J. P. Small W. J. (1969). Studies on manganese III. The biological half-life of radio-manganese in man and factors which affect this half-life. J. Clin. Invest. 47, 643–653.

Robertson R. R. Price R. R. Budinger T. F. Fairbanks V. F. Pollycove M. (1983). Radiation absorbed doses from Iron-52, Iron-55 and Iron-59 used to study ferrokinetics. MIRD Dose Estimate Report No. 11. J. Nucl. Med. 24, 339–348.

Roth P. Werner E. Henrichs K. Elsasser U. Kaul A. (1986). Variations in absorbed doses from ⁵⁹Fe in different diseases. In: Fourth Int. Radiopharmaceutical Dosimetry Symposium, Oak Ridge 1985, Oak Ridge Assoc. Univ. CONF-851113, pp. 310–318. Oak Ridge National Laboratories, Oak Ridge, Tennessee.

Fetal dosimetry.

Dyer N. C. Brill A. B. (1972). Maternal-fetal transport of iron and iodine in human subjects. Adv. Exp. Med. Biol. 27, 351–366.

Beekhuis H. Niewig O. E. (1984). Radiation absorbed doses from Co-57- and Co-55 bleomycin. J. Nucl. Med. 25, 478–485.

Adopted model.

Amin S. Spinks T. Ranicar A. Short M. D. Hoffbrand A. V. (1980). Long-term clearance of (⁵⁷Co) cyanocobalamin in vegans and pernicious anaemia. Clin. Sci. 58, 101–103.

Heyssel R. M. Bozian R. C. Darby W. J. Meneely G. R. (1965). Turnover of ⁶⁰Co-labeled vitamin B₁₂ in patients with pernicious anaemia. In: Radioactivity in Man, Second Symposium, pp. 331–342. ( Meneely G. R. Linde S. M. eds) Charles C. Thomas, Springfield, Illinois.

McEwan A. C. (1974). Patient Radiation Doses from Radiopharmaceuticals, Report of the National Radiation Laboratory, NRL 1974/3. Department of Health, Christchurch, New Zealand.

Powsner E. R. Raeside D. E. (1971). Diagnostic Nuclear Medicine, p. 456. Grune and Stratton, New York.

Reizenstein P. Ek G. Matthews C. M. E. (1966). Vitamin B₁₂ kinetics in man. Implications on total-body-B₁₂-determinations, human requirements, and normal and pathological cellular B₁₂ uptake. Phys. Med. Biol. 11, 295–306.

Transfer to the fetus.

Luhby A. L. Cooperman J. M. Donnenfeld A. M. Herrers J. M. Teller D. N. Wenig J. B. (1958). Observations on the transfer of vitamin B₁₂ from mother to fetus and newborn. AMA J. Dis. Child. 96, 532–533.

Boddy K. Adams J. F. (1968). Excretion of cobalamins and coenzyme B₁₂ following massive parenteral doses. Am. J. Clin. Nutr. 21, 657–666.

Nelp W. B. Wagner H. N. Reba R. C. (1964). Renal excretion of vitamin B₁₂ and its use in measurement of glomerular filtration rate in man. J. Lab. Clin. Med. 63, 480–491.

Weeke E. (1968). ⁵⁷Co-cyanocobalamin in the determination of the glomerular filtration rate. Scan. J. Clin. Lab. Invest. 21, 139–144.

Chanarin I. (1974). The Megaloblastic Anaemias, 2nd edn. Blackwell, Oxford.

ICRP (1975). Report of the Task Group on Reference Man, ICRP Publication 23. Pergamon, Oxford.

Callender S. T. Evans J. R. (1955). The urinary excretion of labelled vitamin B₁₂. Clin. Sci. 14, 295–302.

ICRP (1975). Report of the Task Group on Reference Man, ICRP Publication 23. Pergamon, Oxford.

Bernard S. R. (1973). Dosimetric data for copper. In: Health Physics Division Annual Progress Report, pp. 30–32. Oak Ridge National Laboratory (ORNL), Oak Ridge, Tennessee.

Bernard S. R. (1978). Metabolic model and dosimetric data for copper. Bull. Mathem. Biol. 40, 265–269.

Cartwright G. E. Wintrobe H. M. (1964). Copper metabolism in normal subjects. Am. J. Clin. Nutr. 14, 224–232.

Chervu L. R. Sternlieb I. (1974). Dosimetry of copper radionuclides. J. Nucl. Med. 15, 1011–1013.

Günther K. Lössner V. Lössner J. Biesold D. (1975). The kinetics of copper uptake by the liver in Wilson's disease—Studied by a whole-body counter and a double labelling technique. Eur. Neurol. 13, 395–394.

Osborn S. B. Walshe J. M. (1967). Studies with radioactive copper (64-Cu and 67-Cu) in relation to the natural history of Wilson's disease. Lancet i, 346–350.

Ryo U. Y. Ice R. D. Jones J. D. Beierwaltes W. H. (1975). Relative tissue distribution of radioactivity in rats with endocrine “autonomous” breast carcinomas after 3H-, 99mTc- and 64Cu-Bleomycin. J. Nucl. Med. 16, 127–131.

Underwood E. J. (1977). Trace Elements in Human and Animal Nutrition, 4th edn., pp. 56–108. Academic Press, London.

Wiseman G. (1964). Copper. In: Absorption from the Intestine, Chap. 13, pp. 271–272. Academic Press, London.

Aamodt R. L. Rumble W. F. Johnston G. S. Foster D. Henkin R. I. (1979). Zinc metabolism in humans after oral and intravenous administration of Zn-69m. Am. J. Clin. Nutr. 32, 559–569.

Arvidsson B. Cederblad A. Björn-Rasmussen E. Sandström B. (1978). A radionuclide technique for studies of zinc absorption in man. Int. J. Nucl. Med. Biol. 5, 104–109.

Richmond C. R. Furchner J. E. Trafton G. A. Langham W. H. (1962). Comparative metabolism of radionuclides in mammals—I. Uptake and retention of orally administered Zn-65 by four mammalian species. Health Phys. 8, 481–489.

Siegel E. Graig F. A. Crystal M. M. Siegel E. P. (1961). Distribution of Zn 65 in the prostate and other organs of man. Br. J. Cancer 15, 647–664.

Spencer H. Rosoff B. Feldstein A. Cohn S. H. Gusmano E. (1965). Metabolism of zinc 65 in man. Radiat. Res. 24, 432–445.

MIRD Dose Estimate Report No. 2. (1973). Summary of current radiation dose estimates to humans from 66 Ga-, 67 Ga-, 68 Ga- and 72 Ga-citrate. J. Nucl. Med. 14, 755–756.

ICRP (1981). Limits for Intakes of Radionuclides by Workers, ICRP Publication 30: Part 3. Pergamon, Oxford.

Mealey J. Jr Brownell G. L. Sweet W. H. (1959). Radioarsenic in plasma, urine, normal tissues and intracranial neoplasms. Distribution and turnover after intravenous infection in man. Arch. Neurol. Psychiat. 81, 310–320.

Jereb M. Falk R. Jereb B. Lindhé C. (1975). Radiation dose to the human body from intravenously administered ⁷⁵Se sodium selenite. J. Nucl. Med. 16, 846–850.

Lathrop K. A. Johnston R. E. Blau M. Rothschild E. O. (1972). Radiation dose to humans from ⁷⁵Se-L-selenomethionine: MIRD Pamphlet No. 9. J. Nucl. Med., Suppl. 6.

Deckart H. Ertl S. Blottner A. Tautz M. Weiss J. L. (1984). Retention und Strahlenbelastung nach intravenöser Injektion von Scintadren. In: Radioaktive Isotope in Klinik und Forschung, Vol. 16:2, pp. 663–680. ( Höfer R. Z. Bergmann H. eds) Egermann, Wien.

Hawkins L. A. Britton K. E. Shapiro B. (1980). Selenium 75 selenomethyl-cholesterol: A new agent for quantitative functional scintigraphy of the adrenals: Physical aspects. Br. J. Radiol. 53, 883–889.

Montz R. Hagemann J. Mischke W. (1978). 75-Se-6-Norcholesterol zur Nebennieren-Szintigraphie. In: Nuklearmedizin und Biokybernetik, Vol. II, pp. 231–234. ( Oeff K. Schmidt H. A. E. eds) Medico-Informationsdienste, Berlin.

Heaton K. W. (1976). Clinical aspects of bile acid metabolism. Rec. Adv. Gastroenterol. 3, 199–230.

Jazrawi R. P. Lanzini A. Britten A. Meller S. T. Northfield T. C. (1984). Dynamics of gallbladder function and of the enterohepatic circulation studied by γ labelled bile acid. Clin. Sci. 66, 10P.

Merrick M. V. Eastwood M. A. Ford J. J. (1985). Is bile acid malabsorption underdiagnosed? An evaluation of accuracy of diagnosis by measurement of SeHCAT retention. Br. Med. J. 290, 665–668.

Nyhlin H. Merrick M. V. Eastwood M. A. Brydon W. G. (1983). Evaluation of ileal function using 23-selena-25-homotaurocholate, a γ-labeled conjugated bile acid. Gastroenterology 84, 63–68.

Soundy R. G. Simpson J. D. Ross H. M. Merrick M. V. (1982). Absorbed dose to man from the Se-75 labeled conjugated bile salt SeHCAT. J. Nucl. Med. 23, 157–161.

ICRP (1980). Limits for Intakes of Radionuclides by Workers, ICRP Publication 30: Part 2. Pergamon, Oxford.

Crawley J. C. W. Smith T. Veall N. Zanelli G. D. (1984). Distribution, retention and radiation dosimetry of ⁷⁷Br-p-bromo-spiperone. Radiat. Prot. Dosim. 8, 147–153.

Myers M. J. (1981). The practical estimation of internal radiation doses from ⁸¹Kr^m, and similar ultra-short lived radionuclides. Nucl. Med. Commun. 2, 358–363.

Ostertag H. Kübler W. K. Knopp W. A. (1984). Strahlen-exposition bei der Anwendung von Kr-81m. In: Nuklearmedizin, pp. 401–404. ( Schmidt H. A. E. Adam W. E. eds) F. K. Schattauer, Stuttgart.

Swanson A. L. Mayron L. W. Kaplan E. (1976). Radiation dosimetry for krypton-81m. Int. J. Nucl. Med. Biol. 3, 140–142.

Yano Y. McRae J. Anger H. O. (1971). Generator-produced krypton-81m for dynamic studies of the lungs and heart with the scintillation camera. In: Radiopharmaceuticals from Generator-produced Radionuclides, pp. 97–104. International Atomic Energy Agency, Vienna.

Ryan J. W. Harper P. V. Stark V. S. Peterson E. L. Lathrop K. A. (1986). Radiation absorbed dose estimate for Rubidium-82 determined from in vivo measurements in human subjects. In: Proc. Fourth Int. Radiopharmaceutical Dosimetry Symposium, Oak Ridge, Tennessee, November 1985, Oak Ridge Associated Universities CONF-851113 (DE 86010102), pp. 346–358. Oak Ridge National Laboratories, Oak Ridge, Tennessee.

Spector W. S. (1956). Handbook of Biological Data. W. B. Saunders, Philadelphia.

ICRP (1980). Limits for Intakes of Radionuclides by Workers, ICRP Publication 30: Part 2. Pergamon, Oxford.

Lloyd R. D. Mays C. W. McFarland S. S. Zundel W. S. Tyler F. H. (1973). Metabolism of Rb-83 and Cs-137 in persons with muscle disease. Radiat. Res. 54, 463–478.

Nagai T. Sugita H. Iinuma T. A. Furukawa T. Yashiro S. (1968). Body-potassium concentration and rubidium metabolism determined by whole-body counting in Duchenne muscular dystrophy and its genetic carrier state. J. Nucl. Med. 10, 1–7.

Ray C. T. Threefoot S. A. Burch G. E. (1955). The excretion of radiorubidium, Rb-86, radiopotassium, K-42, and potassium, sodium and chloride by man with and without congestive heart failure. J. Lab. Clin. Med. 45, 408–430.

Strauss H. W. Harrison K. Langan J. K. Lebowitz E. Pitt B. (1975). Thallium-201 for myocardial imaging. Circulation 51, 641–645.

Wood O. L. (1969). Comparison of naturally occurring rubidium and potassium in human erythrocytes, plasma and urine. Health Phys. 17, 513–514.

Szur L. Glass H. I. Lewis S. M. Grammaticos O. de Garreta A. C. (1968). Quantative estimation of red-cell uptake in the spleen using ⁸¹Rb and ⁵¹Cr-labelled red cells. Br. J. Radiol. 41, 819–825.

Bishop M. Harrison G. E. Raymond W. H. A. Sutton A. (1960). Excretion and retention of radioactive strontium in normal men following a single intravenous injection. Int. J. Radiat. Biol. 2, 125–142.

Harrison G. E. Carr T. E. F. Sutton A. (1967). Distribution of radioactive calcium, strontium, barium and radium following intravenous injection into a healthy man. Int. J. Radiat. Biol. 13, 235–247.

ICRP (1972). Report of the ICRP Task Group on Alkaline Earth Metabolism in Adult Man, ICRP Publication 20. Pergamon, Oxford.

ICRP (1979). Limits for Intakes of Radionuclides by Workers, ICRP Publication 30: Part 1. Pergamon, Oxford.

Russell J. T. Hibbard H. B. M. Sheppard M. A. (1969). Metabolic behaviour and radiation dosimetry of 99m Tc-albumin in pregnancy. J. Nucl. Med. 10, 224–232.

Ashburn W. L. Harbert J. C. Briner W. H. Di Chiro G. (1968). Cerebrospinal fluid rhinorrhea studied with the gamma scintillation camera. J. Nucl. Med. 9, 523–529.

99mTc Solcocitran, product information: N-MED AG, Nuklearmedizinische Präparate, Postfach 186, 8030 Zürich.

Arnold R. W. Subramanian G. McAfee J. G. Blair R. J. Thomas F. D. (1975). Comparison of ^99mTc complexes for renal imaging. J. Nucl. Med. 16, 357–367.

Elliott A. T. Britton K. E. Brown N. J. G. Pearce P. C. Smith F. R. Barnasconi E. W. (1976). Dosimetry of current radiopharmaceuticals used in renal investigation. Proc. Radiopharmaceutical Dosimetry Symposium, Oak Ridge, Tennessee, April 26–29, 1976, HEW Publication (FDA) 76–8044, pp. 293–304. U.S. Department of Health and Welfare, Washington, DC.

Enlander D. Weber P. M. dos Remedios L. V. (1974). Renal cortical imaging in 35 patients: Superior quality with ^99mTc-DMSA. J. Nucl. Med. 15, 743–749.

Handmaker H. Young B. W. Lowenstein J. M. (1975). Clinical experience with ^99mTc-DMSA [Dimercaptosuccinic acid], a new renal imaging agent. J. Nucl. Med. 16, 28–32.

Klopper J. F. Hauser W. Atkins H. L. Eckelman W. C. Richards P. (1972). Evaluation of ^99mTc-DTPA for the measurement of glomerular filtration rate. J. Nucl. Med. 13, 107–110.

McAfee J. G. Gagne G. Atkins H. L. Kirchner P. T. Reba R. C. Blaufox M. D. Smith E. M. (1979). Biological distribution and excretion of DTPA labelled with Tc-99m and In-111. J. Nucl. Med. 20, 1273–1278.

O'Reilly P. H. Shields R. A. Testa H. J. (1979). Nuclear Medicine in Urology and Nephrology. Butterworths, London.

Som P. Hosain F. Wagner H. N. Jr Scheffel U. (1972). Cisternography with chelated complex of ^99mTc. J. Nucl. Med. 13, 551–553.

Khan O. Ell P. J. Cullum I. D. Jarritt P. H. Williams E. S. (1981). Clinical and pharmacological studies with ^99mTc-plasmin. In: Progress in Radiopharmacology, Vol. 2, pp. 157–171. ( Cox P. H. ed.) Elsevier, Amsterdam.

Persson B. Olsson C. G. Darte L. Strand S. E. Bergqvist L. Stahlberg F. (1981). Preparation and testing of ⁹⁹Tc^m-labelled plasmin for thrombus detection. In: Progress in Radiopharmacology, Vol. 2, pp. 147–156. ( Cox P. H. ed.) Elsevier, Amsterdam.

Arnold R. W. Subramanian G. McAfee J. G. Blair R. J. Thomas F. D. (1975). Comparison of ⁹⁹Tc^m complexes for renal imaging. J. Nucl. Med. 16, 357–367.

Boyd R. E. Robson J. Hunt F. C. Sorby P. J. Murray I. P. C. McKay W. J. (1973). ⁹⁹Tc^m gluconate complexes for renal scintigraphy. Br. J. Radiol. 46, 604–612.

Hagan P. L. Chauncey D. M. Halpern S. E. Ayres P. R. (1977). ⁹⁹Tc^m-thiomalic acid complex: A nonstannous chelate for renal scanning. J. Nucl. Med. 18, 353–359.

Halpern S. Tubis M. Endow J. Walsh C. Kunsa J. Zwicker B. (1972). ⁹⁹Tc^m-Penicillamine-Acetazolamide complex, a new renal scanning agent. J. Nucl. Med. 13, 45–50.

Halpern S. E. Tubis M. Golden M. Kunsa J. Endow J. Walsh C. (1972). ^99mTc PAC, a new renal scanning agent. II. Evaluation in humans. J. Nucl. Med. 13, 723–728.

Taylor A. Davis G. Halpern S. Ashburn W. (1977). ^99mTechnetium Penicillamine, a renal cortical scanning agent. J. Urol. 117, 418–420.

Andros G. Harper P. V. Lathrop K. A. McCardle R. J. (1965). Pertechnetate-99m localisation in man with application to thyroid scanning and the study of thyroid physiology. J. Clin. Endocrinol. 25, 1067–1076.

Beasley T. M. Palmer H. E. Nelp W. B. (1966). Distribution and excretion of technetium in humans. Health Phys. 12, 1425–1435.

Coffey J. L. Hayes R. L. Rafter J. J. Watson E. E. Carlton J. E. (1984). Radiation dosimetry and chemical toxicity considerations for ⁹⁹Tc. Health Phys. 46, 418–422.

Dayton D. A. Maher F. T. Elveback L. R. (1969). Renal clearance of technetium (^99mTc) as pertechnetate. Mayo Clin. Proc. 44, 549–551.

ICRP (1980). Limits for Intakes of Radionuclides by Workers, ICRP Publication 30: Part 2. Pergamon, Oxford.

MIRD Dose Estimate Report No. 8 (1976). Summary of current radiation dose estimates to normal humans from ^99mTc as sodium pertechnetate. J. Nucl. Med. 17, 74–77.

Jonckheer M. H. Vandenbrock M. van den Brande P. (1981). The biological behaviour of technetium labelled fibrinogen with reference to thrombus localisation. In: Progress in Radiopharmacology, Vol. 2, pp. 127–136. ( Cox P. H. ed.) Elsevier, Amsterdam.

Callahan R. J. Froelich J. W. McKusick K. A. Leppo J. Strauss W. H. (1982). A modified method for the in vivo labeling of red blood cells with Tc-99m: Concise communication. J. Nucl. Med. 23, 315–318.

Dahlström J. A. Carlsson S. Lilja B. Mattsson S. Pettersson C. (1979). Cardiac blood pool imaging—A clinical comparison between red blood cells labeled with ^99mTc in vivo and in vitro and ^99mTc-labeled human serum albumin. Nuklearmedizin 18, 271–273.

Larson S. M. Hamilton G. W. Richards P. Ritchie J. L. (1978). Kit-labeled technetium-99m red blood cells (Tc-99m-RBC's) for clinical cardiac chamber imaging. Eur. J. Nucl. Med. 3, 227–231.

Porter W. C. Dees S. M. Freitas J. E. Dworkin H. J. (1983). Acid-citrate-dextrose compared with heparin in the preparation of in vivo/in vitro technetium-99m red blood cells. J. Nucl. Med. 24, 383–387.

Ryo U. Y. Pinsky S. M. (1976). Radionuclide angiography with 99m Technetium-RBC's. In: Crit. Rev. Clin. Radiol. Nucl. Med. 8, 107–128.

Atkins H. L. Goldman A. G. Fairchild R. G. Oster Z. H. Som P. Richards O. Meinken G. E. Srivastava S. C. (1980). Splenic sequestration of ^99mTc-labeled, heat-treated red blood cells. Radiology 136, 501–503.

Ackerhalt R. E. Blau M. Bakshi S. Sondel J. A. (1974). A comparative study of three 99mTc-labeled phosphorus compounds and 18F-fluoride for skeletal imaging. J. Nucl. Med. 15, 1153–1157.

Fogelman F. Bessent R. G. Turner J. G. Citrin D. L. Boyle I. T. Greig W. R. (1978). The use of whole body retention of Tc99m diphosphonate in the diagnosis of metabolic bone disease. J. Nucl. Med. 19, 270–275.

Krishnamurthy G. T. Huebotter R. J. Walsh C. F. Taylor J. R. Kehr M. D. Tubis M. Blahd W. H. (1975). Kinetics of 99mTc-labeled pyrophosphate and polyphosphate in man. J. Nucl. Med. 16, 109–115.

Makler P. T. Charkes N. D. (1980). Studies of skeletal tracer kinetics IV. Optimum time delay for Tc-99m (Sn) methylene diphosphonate bone imaging. J. Nucl. Med. 21, 641–645.

Rudd T. G. Allen D. R. Hartnett D. E. (1977). Tc99m methylene diphosphonate versus Tc99m pyrophosphate: Biologic and clinical comparison. J. Nucl. Med. 18, 872–876.

Subramanian G. McAfee J. G. Blair R. J. Kallfelz F. Thomas F. D. (1975). Technetium 99m methylene diphosphate—A superior agent for skeletal imaging. Comparison with other technetium complexes. J. Nucl. Med. 16, 744–755.

Barber R. W. (1985). Radiation doses from technetium-99m DTPA administered as an aerosol. J. Nucl. Med. 26, 1190–1194.

Coates G. O'Brodovich H. (1986). Measurement of pulmonary epithelial permeability with ^99mTc-DTPA aerosol. Semin. Nucl. Med. 16, 275–284.

Cook D. J. Lander H. (1971). Inhalation pulmonary scintiphotography using pertechnetate. Am. J. Roentgenol. 113, 682–689.

Jones J. G. Lawler P. Crawley J. C. W. Minty B. D. Hulands G. Veall N. (1980). Increased alveolar epithelial permeability in cigarette smokers. Lancet i, 66–68.

Köhn H. Klech H. Angelberger P. Strigl A. Zolle I. Kummer F. Mostbeck A. (1985). Dry aerosol of monodisperse millimicrospheres for ventilation imaging: Production, delivery system, and clinical results in comparison with 81m-krypton and 127-xenon. Eur. J. Nucl. Med. 10, 411–416.

Kotrappa P. Raghunath B. Subramanyam P. S. S. Raikar U. R. Sharma S. M. (1977). Scintiphotography of lungs with dry aerosol-generation and delivery system: Concise communication. J. Nucl. Med. 18, 1082–1085.

Pircher F. J. Knight C. M. Barry W. F. Temple J. R. Kirsch W. J. (1967). Retention, distribution and absorption of inhaled albumin aerosol and absorbed dose estimates from its I¹³¹ and Tc^99m labels. Am. J. Roentgenol. 100, 813–821.

Taplin G. V. Chopra S. K. (1978). Lung perfusion-inhalation scintigraphy in obstructive airway disease and pulmonary embolism. Radiol. Clin. N. Am. 16, 491–513.

Esquerré J. P. Boneu B. Guiraud R. (1979). Kinetics of technetium-labeled heparin in thromboembolism: Preliminary report. Int. J. Nucl. Med. Biol. 6, 215–220.

Kulkarni P. V. Parkey R. W. Buja L. M. Wilson J. E. III Bonte F. J. Willerson J. T. (1978). Technetium-labeled heparin: Preliminary report of a new radiopharmaceutical with potential for imaging damaged coronary arteries and myocardium. J. Nucl. Med. 19, 810–815.

Utne H. E. Pors Nielsen S. de Schrijver M. (1981). ^99mTechnetium-Heparin: Radiopharmacokinetic and clinical aspects. In: Progress in Radiopharmacology, Vol. 2, pp. 193–201. ( Cox P. H. ed.) Elsevier, Amsterdam.

Chadhuri T. K. (1974). Use of 99m Tc-DTPA for measuring gastric emptying time. J. Nucl. Med. 15, 391–395.

Fisher R. S. Malmud L. S. Roberts G. S. Lobis I. F. (1976). Gastroesophageal (GE) scintiscanning to detect and quantitate GE reflux. Gastroenterology 70, 301–308.

Meyer J. H. MacGregor I. L. Gueller R. Martin P. Cavalieri R. (1976). ^99mTc-tagged chicken liver as a marker of solid food in the human stomach. Am. J. Dig. Dis. 21, 296–304.

Blau M. Wicks R. Thomas S. R. Lathrop K. A. (1982). MIRD dose estimate report No. 10. Radiation absorbed dose from albumin microspheres labeled with technetium-99m. J. Nucl. Med. 23, 915–917.

Wicks R. Rosenspire K. Ackerhalt R. Langan M. Steinbach J. J. Blau M. (1981). Distribution of Tc-99m administered as labeled microspheres for lung imaging. In: Proc. Third Int. Radiopharmaceutical Dosimetry Symposium, Oak Ridge, 1980, pp. 454–463, FDA 81-8166. Oak Ridge National Laboratories, Oak Ridge, Tennessee.

Hanna R. Braun T. Levendel A. Lomas F. (1984). Radiochemistry and biostability of autologous leukocytes labelled with ^99mTc-stannous colloid in whole blood. Eur. J. Nucl. Med. 9, 216–219.

Kelbaek H. Fogh J. Gjorup T. Bülow K. Vestergaard B. (1985). Scintigraphic demonstration of subcutaneous abscesses with ^99mTc-labeled leukocytes. Eur. J. Nucl. Med. 10, 302–303.

Schroth H. J. Oberhausen E. Berberich R. (1981). Cell labelling with colloidal substances in whole blood. Eur. J. Nucl. Med. 6, 469–472.

Castronovo F. P. Wagner H. N. (1971). Factors affecting the toxicity of the element indium. Br. J. Exp. Pathol. 52, 543–559.

Castronovo F. P. Wagner H. N. (1973). Comparative toxicity and pharmacodynamics of ionic indium chloride and hydrated indium oxide. J. Nucl. Med. 14, 677–682.

ICRP (1980). Limits for Intakes of Radionuclides by Workers, ICRP Publication 30: Part 2. Pergamon, Oxford.

McAfee J. G. Subramanian G. (1975). Radioactive agents for imaging. In: Clinical Scintillation Imaging, p. 62. ( Freeman L. M. Johnson P. M. eds) Grune and Stratton, New York.

McAfee J. G. Gagne G. Atkins H. L. Kirchner P. T. Reba R. C. Blaufox M. D. Smith E. M. (1974). Biological distribution and excretion of DTPA labelled with Tc-99m and In-111. J. Nucl. Med. 20, 1273–1278.

O'Mara R. E. Subramanian G. McAfree J. G. Burger C. L. (1969). Comparison of ^113mIn and other short lived agents for cerebral scanning. J. Nucl. Med. 10, 18–27.

Sziklas J. J. Hosain F. Reba R. C. Wagner H. N. (1971). Comparison of ¹⁶⁹Yb-DTPA, ^113mIn-DTPA, ¹⁴C-inulin and endogenous creatinine to estimate glomerular filtration. J. Nucl. Biol. Med. 15, 122–125.

Isawa T. Hayes M. Taplin G. V. (1971). Radioaerosol inhalation lung scanning: Its role in suspected pulmonary embolism. J. Nucl. Med. 12, 606–609.

Fazio F. Wollmer P. Lavender J. P. Barr M. M. (1982). Clinical ventilation imaging with In-113m aerosol: A comparison with Kr-81m. J. Nucl. Med. 23, 306–314.

Goodwin D. A. Song C. H. Finston R. Matin P. (1973). Preparation, physiology, and dosimetry of ¹¹¹In-labeled radiopharmaceuticals for cisternography. Radiology 108, 91–98.

Isawa T. Hayes M. Taplin G. V. (1971). Radioaerosol inhalation lung scanning: Its role in suspected pulmonary embolism. J. Nucl. Med. 12, 606–609.

Fazio F. Wollmer P. Lavender J. P. Barr M. M. (1982). Clinical ventilation imaging with In-113m aerosol: A comparison with Kr-81m. J. Nucl. Med. 23, 306–314.

Heading R. C. Tothill P. Laidlaw A. J. Shearman D. J. C. (1971). An evaluation of ^113mindium DTPA chelate in the measurement of gastric emptying by scintiscanning. Gut 12, 611–615.

Wright R. A. Thompson D. Syed I. (1981). Simultaneous markers for fluid and solid gastric emptying: New variations on an old theme: Concise communication. J. Nucl. Med. 22, 772–776.

Goodwin D. A. Bushberg J. T. Doherty P. N. Lipton M. J. Conley F. K. Diamanti C. I. Meares C. F. (1978). Indium-111-labeled autologous platelets for location of vascular thrombi in humans. J. Nucl. Med. 19, 626–634.

Klonizakis I. Peters A. M. Fitzpatrick M. L. Kensett M. L. Lewis S. M. Lavender J. P. (1980). Radionuclide distribution following injection of ¹¹¹Indium-labelled platelets. Br. J. Haematol. 46, 595–602.

Robertson J. S. Dewanjee M. K. Brown M. L. Fuster V Chesebro J. H. (1981). Distribution and dosimetry of ¹¹¹In-labeled platelets. Radiology 140, 169–176.

Scheffel U. Tsan M.-F. Mitchell T. G. Camargo E. E. Braine H. Ezekowitz M. D. Nickoloff E. L. Hill-Zobel R. Murphy E. McIntyre P. A. (1982). Human platelets labeled with In-111 8-Hydroxyquinoline: Kinetics, distribution, and estimates of radiation dose. J. Nucl. Med. 23, 149–156.

Schmidt K. G. Rasmussen J. W. Rasmussen A. D. (1985). Kinetics of ¹¹¹In-labelled platelets in healthy subjects. Scand. J. Haematol. 34, 370–377.

Wessels P. Heyns A. du P. Pieters H. Lötter M. G. Badenhorst P. N. (1985). An improved method for the quantification of the in vivo kinetics of a representative population of ¹¹¹In-labelled human platelets. Eur. J. Nucl. Med. 10, 522–527.

Goodwin D. A. Finston R. A. Smith S. I. (1981). The distribution and dosimetry of In-111 labeled leucocytes and platelets in humans. In: Proc. Third Int. Radiopharmaceutical Dosimetry Symposium, Oak Ridge, 1980 (FDA 81-8166), pp. 88–101. Oak Ridge National Laboratories, Oak Ridge, Tennessee.

Mountford P. J. Allsopp M. J. Hall F. M. Wells C. P. Coakley A. J. (1985). Leucocyte and contaminant cell-bound activities resulting from the labelling of leucocytes with ¹¹¹In-oxine. Eur. J. Nucl. Med. 10, 304–307.

Saverymuttu S. H. Peters A. M. Keshavarzian A. Reavy H. J. Lavender J. P. (1985). The kinetics of ¹¹¹Indium distribution following injection of ¹¹¹Indium labelled autologous granulocytes in man. Br. J. Haematol. 61, 675–685.

Thakur M. L. Seifert C. L. Madsen M. T. McKenney S. M. Desai A. G. Park C. H. (1984). Neutrophil labeling: Problems and pitfalls. Semin. Nucl. Med. 14, 107–117.

Weiblen B. J. Forstrom L. McCullough J. (1979). Studies of the kinetics of indium-111-labeled granulocytes. J. Lab. Clin. Med. 94, 246–255.

Thakur M. L. Merrick M. V. Gunasekera S. W. (1973). Some pharmacological aspects of a new radiopharmaceutical, ¹¹¹In-bleomycin. In: Radiopharmaceuticals and Labelled Compounds, Vol. II, pp. 183–193, International Atomic Energy Agency, Vienna.

Trott N. G. O'Connell M. E. A. Ross H. A. Smith P. H. S. Taylor D. M. (1974). Some studies of the dosimetry and safety of radiopharmaceuticals. In: Radioaktive Isotope in Klinik und Forschung, Vol. 11, pp. 1–18. ( Höfer R. ed.) Urban and Schwarzenberg, München.

Williams E. D. Merrick M. V. Lavender J. P. (1975). The distribution and dosimetry of ¹¹¹In-bleomycin in man. Br. J. Radiol. 48, 275–278.

Model for adults and children.

Berman M. Hoff E. Barandes M. Becker D. V. Sonenberg M. Benua R. Koutras D. A. (1968). J. Clin. Endocrinol. Metab. 28, 1–14.

Kaul A. Oeff K. Roedler H. D. Vogelsang T. (1973). Radiopharmaceuticals—Biokinetic Data and Results of Radiation Dose Calculations. Informationsdienst für Nuklearmedizin, Berlin.

MIRD Dose Estimate Report No. 5 (1975). Summary of current radiation dose estimates to humans from ¹²³I, ¹²⁴I, ¹²⁵I, ¹²⁶I, ¹³⁰I, ¹³¹I and ¹³²I as sodium iodide. J. Nucl. Med. 16, 857–860.

Riggs D. S. (1952). Quantitative aspects of iodine metabolism in man. Pharmacol. Rev. 4, 284–370.

Stather J. W. Greenhalgh J. R. (1983). The Metabolism of Iodine in Children and Adults, NRPB-R140. National Radiological Protection Board, Chilton.

Takeda Y. Reeve B. M. (1962). Distribution and excretion of I¹³¹-iodide in men on pharmacologic doses of iodides. J. Lab. Clin. Med. 60, 944–953.

Wootton R. Hammond B. J. (1978). A computer simulation study of optimal thyroid radiation protection during investigations involving the administration of radioiodine-labelled pharmaceuticals. Br. J. Radiol. 51, 265–272.

Dosimetry of the fetal thyroid.

Aboul Khair S. A. Buchanan T. J. Crooks J. Turnbull A. C. (1966). Structural and functional development of the human fetal thyroid. Clin. Sci. 31, 415–424.